Novel Antimicrobials and the Antimicrobial Activity: New Advances
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 October 2024 | Viewed by 89
Special Issue Editors
Interests: antimicrobial resistance; resistance mechanisms; molecular microbiology; antimicrobial activity; carbapenem resistance
Interests: antimicrobial resistance; antibiotics; resistance mechanisms; difficult-to-treat pathogens; carbapenem resistance; Acinetobacter baumannii
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antibiotic therapy is a key weapon in the eradication of infections throughout communities and hospital settings. The increasingly alarming worldwide phenomenon of antibiotic resistance complicates the drafting of antibiotic therapy plans. Gram-negative carbapenem-resistant (GN-CRE) bacteria, vancomycin-resistant Enterococcus faecium (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) cause the most deaths from infections worldwide. Phenotypic and genotypic knowledge of these multidrug-resistant microorganisms as well as their mechanisms of resistance are crucial. At the same time, the multidisciplinary development of new antibiotic molecules that can counteract antibiotic resistance is crucial in order to develop new treatment modalities for precision medicine that can overcome antibiotic resistance mechanisms. This Special Issue aims to provide up-to-date basic and clinical research, reviews and communications on new antibiotic molecules from microbiological, pharmacokinetic/pharmacodynamic and clinical points of view in order to strategically implement and stratify treatment plans for MDR infections.
Dr. Davide Carcione
Dr. Luigi Principe
Dr. Cattaneo Dario
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multi-drug resistance
- infection
- mechanism of action
- resistance mechanisms
- therapeutic medicine
- diagnostic tools
- antimicrobial stewardship
- pharmacokinetics/pharmacodynamics
